Literature DB >> 19433310

Cathepsin X cleaves the C-terminal dipeptide of alpha- and gamma-enolase and impairs survival and neuritogenesis of neuronal cells.

Natasa Obermajer1, Bojan Doljak, Polona Jamnik, Ursa Pecar Fonović, Janko Kos.   

Abstract

The cysteine carboxypeptidase cathepsin X has been recognized as an important player in degenerative processes during normal aging and in pathological conditions. In this study we identify isozymes alpha- and gamma-enolases as targets for cathepsin X. Cathepsin X sequentially cleaves C-terminal amino acids of both isozymes, abolishing their neurotrophic activity. Neuronal cell survival and neuritogenesis are, in this way, regulated, as shown on pheochromocytoma cell line PC12. Inhibition of cathepsin X activity increases generation of plasmin, essential for neuronal differentiation and changes the length distribution of neurites, especially in the early phase of neurite outgrowth. Moreover, cathepsin X inhibition increases neuronal survival and reduces serum deprivation induced apoptosis, particularly in the absence of nerve growth factor. On the other hand, the proliferation of cells is decreased, indicating induction of differentiation. Our study reveals enolase isozymes as crucial neurotrophic factors that are regulated by the proteolytic activity of cathepsin X.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19433310     DOI: 10.1016/j.biocel.2009.02.019

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  25 in total

Review 1.  Cysteinyl cathepsins in cardiovascular diseases.

Authors:  Xian Zhang; Songyuan Luo; Minjie Wang; Guo-Ping Shi
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-01-09       Impact factor: 3.036

Review 2.  Transglutaminase 2: Friend or foe? The discordant role in neurons and astrocytes.

Authors:  Breandan R Quinn; Laura Yunes-Medina; Gail V W Johnson
Journal:  J Neurosci Res       Date:  2018-03-23       Impact factor: 4.164

3.  Development of activity-based probes for cathepsin X.

Authors:  Margot G Paulick; Matthew Bogyo
Journal:  ACS Chem Biol       Date:  2011-02-28       Impact factor: 5.100

Review 4.  Cysteine cathepsins in neurological disorders.

Authors:  Anja Pišlar; Janko Kos
Journal:  Mol Neurobiol       Date:  2013-11-15       Impact factor: 5.590

Review 5.  DNA Methylation: a New Player in Multiple Sclerosis.

Authors:  Xiang Li; Bing Xiao; Xing-Shu Chen
Journal:  Mol Neurobiol       Date:  2016-06-17       Impact factor: 5.590

6.  Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains.

Authors:  Jimmy L Huynh; Paras Garg; Tin Htwe Thin; Seungyeul Yoo; Ranjan Dutta; Bruce D Trapp; Vahram Haroutunian; Jun Zhu; Michael J Donovan; Andrew J Sharp; Patrizia Casaccia
Journal:  Nat Neurosci       Date:  2013-11-24       Impact factor: 24.884

7.  Application of a Sulfoxonium Ylide Electrophile to Generate Cathepsin X-Selective Activity-Based Probes.

Authors:  Simon J Mountford; Bethany M Anderson; Bangyan Xu; Elean S V Tay; Monika Szabo; My-Linh Hoang; Jiayin Diao; Luigi Aurelio; Rhiannon I Campden; Erik Lindström; Erica K Sloan; Robin M Yates; Nigel W Bunnett; Philip E Thompson; Laura E Edgington-Mitchell
Journal:  ACS Chem Biol       Date:  2020-02-14       Impact factor: 5.100

Review 8.  α-Enolase, a multifunctional protein: its role on pathophysiological situations.

Authors:  Angels Díaz-Ramos; Anna Roig-Borrellas; Ana García-Melero; Roser López-Alemany
Journal:  J Biomed Biotechnol       Date:  2012-10-14

9.  Cathepsin X in serum from patients with colorectal cancer: relation to prognosis.

Authors:  Tjasa Vizin; Ib Jarle Christensen; Hans Jørgen Nielsen; Janko Kos
Journal:  Radiol Oncol       Date:  2012-07-24       Impact factor: 2.991

10.  Profilin 1 as a target for cathepsin X activity in tumor cells.

Authors:  Urša Pečar Fonović; Zala Jevnikar; Matija Rojnik; Bojan Doljak; Marko Fonović; Polona Jamnik; Janko Kos
Journal:  PLoS One       Date:  2013-01-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.